SEC Form 4 · accession 0001209191-15-080951
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Nov 16, 2015
Accepted (ET)
Nov 18, 2015 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 16, 2015 | M | 3,650 | $77.31 | A | 108,541 | D | |
| Common Stock | Nov 16, 2015 | S | 184 | $121.95 | D | 108,357 | D | |
| Common Stock | Nov 16, 2015 | S | 143 | $122.47 | D | 108,214 | D | |
| Common Stock | Nov 16, 2015 | S | 100 | $123.00 | D | 108,114 | D | |
| Common Stock | Nov 16, 2015 | S | 3,650 | $124.00 | D | 104,464 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $77.31 | Nov 16, 2015 | M | 3,650 | D | — | Feb 4, 2024 | Common Stock | 3,650 | 38,250 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 02/05/2014.